However, in the absence of head-to-head treatment comparison, confidence in these estimates is low. Future head-to-head treatment comparison trails and comparative effectiveness observational studies in a homogenous cohort are warranted.
SIRS, We thank Singh et al. for their thoughtful letter. 1 This highlights three aspects of our manuscript that we believe deserve further discussion. 2 First, although we agree that inclusion of vedolizumab, an anti-integrin therapeutic, is a potential option, we elected to focus on comparing anti-tumour necrosis factor (anti-TNF) agents to limit issues of clinical and biologic heterogeneity. Second, we found the definitions and reporting of prior anti-TNF exposure to be inconsistent between studies (e.g. prior anti-TNF permitted but data not reported, variable washout lengths). While we documented reported anti-TNF exposure in Table 1 , we were unable to meaningfully analyse patients by prior anti-TNF exposure. Finally, the authors raise concerns over using a clinical endpoint (Mayo score or ulcerative colitis symptom score) as the primary outcome measure in our meta-analysis. Although we agree that objective measures are preferred, the clinical trials available for inclusion in our network meta-analysis were designed and powered based on clinical activity indices.
The results of Singh et al.'s work reported similar findings to our analysis -that available clinical trial data do not demonstrate significant differences in efficacy between anti-TNF agents, and potentially vedolizumab. This discussion points out important limitations of the available data, highlighting the need for objective and reproducible measures of disease activity in ulcerative colitis clinical trials. Head-to-head studies are needed to better understand the comparative efficacy of therapies for ulcerative colitis.
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The authors' declarations of personal and financial interests are unchanged from those in the original article. To evaluate whether these two devices could be considered equivalent, we perform a cross-sectional prospective study in our clinic. All consecutive HCV infected patients attending our unit had consecutive liver stiffness measurement with FS502 and FS402, on the same area and by the same observer. Agreement between FS502 and FS402 was characterised using the Kappa index 3 for four cut-offs values: <7.2 kPa (F1), 7.2-12.4 kPa (F2-F3) and >12.4 kPa (F4) 4 and for significant fibrosis (9 kPa). 5 We included 101 patients, mostly men (72 men vs. 29 women) and with a mean BMI: of 25.2 AE 0.85 kg/m 2 .
Concordance between FS502 and FS402 is shown in Figure 1 .
No statistically significant differences were obtained for F1 and F4 measurements, with strong correlation [n = 52; rho Spearman (r s ): 0.827; P = 0.01 and n = 28; r s : 0.935; P = 0.001 respectively] and substantial agreement between both devices (Kappa 0.781; P < 0.001 and 0.923; P < 0.001, respectively). For F2-F3 stages, there was a significant difference between both devices (median 9.4 vs. 8 for FS502 and FS402, respectively; P = 0.024). There was also a strong correlation substantial agreement between both devices, although to a lesser extent (n = 35; r s : 0.737; P = 0.01 and Kappa 0.654; P < 0.001).
Regarding presence or absence of significant fibrosis, 5 we found a very strong correlation (n = 101; r s : 0.861; P < 0.001) and an almost perfect agreement between FS502 and FS402 (Kappa: 0.856 P < 0.001). Globally, although FS402 might underestimate the degree of fibrosis, as median values are statistically significantly higher with FS502, when stratifying for presence or absence of fibrosis, we found almost perfect agreement and a very strong correlation, suggesting that these differences, although statistically significant, are clinically irrelevant and, from a clinical interpretation of results, both devices can be considered as equivalent. Columns represent percentages of concordance.
